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ABSTRACT 
 
 
Diabetic retinopathy is the leading cause of blindness in working Americans.  
While there are therapeutic regimens for the disease, more effective methods are needed.  
We have previously shown that a non-specific beta-adrenergic receptor agonist, 
isoproterenol, was effective in preventing functional and morphological changes 
associated with diabetic retinopathy in the rat.  Isoproterenol also produced left ventricle 
remodeling suggesting it entered the systemic circulation.  We therefore synthesized 
various novel beta-adrenergic receptor compounds and screened these compounds in 
vitro for their ability to reduce markers of inflammation and apoptosis.  Of the various 
compounds tested, Compound 49b was able to reduce both inflammation and apoptosis in 
vitro in both retinal endothelial cells (REC) and Müller cells and did so at a significantly 
lower concentration than isoproterenol, deeming it the most effective compound. 
  
Objective.  We evaluated the effectiveness of Compound 49b to prevent and 
delay changes associated with diabetic retinopathy without systemic effects.  We 
hypothesized that topical application of Compound 49b could prevent and delay the onset 
of functional and morphological markers of diabetic retinopathy and restore retinal 
cellular signaling, without affecting the heart. 
  
Methods.  Male rats were made diabetic with a streptozotocin injection 
(60mg/kg).  Two days after the injection, glucose measurements were obtained.  Two 
groups of rats were used for these two separate studies.  In the prevention studies, a 
subset of the diabetic rats were started on daily 1mM Compound 49b eye drops for either 
2-months or 8-months upon the verification of diabetes, while the control and diabetic 
only subgroups received no treatment.  In the delayed treated studies, animals were 
placed on Compound 49b after 6-months of untreated diabetes.  Once optimal dose and 
time course was obtained, body weight, blood glucose, intraocular pressure, blood 
pressure, and electrical activity of the retina were measured monthly over the duration of 
the prevention and delayed treatment studies.  Insulin signaling, tumor necrosis 
factor-alpha (TNF-!) levels, and cleavage of caspase 3 were analyzed after 2- and 
8-months or 2- and 6-months of treatment. 
 
Results.  Protein levels of TNF-! and cleaved caspase 3 were increased in the 
retinas of diabetic rats, but were returned to normal values following 1mM Compound 
49b treatment.  Since we have previously found that topical isoproterenol produced left 
ventricular remodeling, we wanted to investigate whether Compound 49b could 
overcome this obstacle.  Left ventricular samples from diabetes+Compound 49b-treated 
rats were not significantly different than diabetes alone rats after statistical analyses.  
 
Conclusion.  Data showed that daily topical 1mM Compound 49b eye drops 
reduced TNF-! levels and cleaved caspase 3 levels, while maintaining insulin receptor 
signal transduction in the diabetic retina.  Additionally, Compound 49b maintained 
retinal electrical activity, as measured by electroretinogram (ERG) analysis.  Data 
indicates that Compound 49b does not reach the systemic circulation or alter blood 
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pressure or intraocular pressure, suggesting that it may represent a novel treatment option 
for diabetic retinopathy. 
 vii 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION.....................................................................................1!
CHAPTER 2. LITERATURE REVIEW.........................................................................3!
Beta-Adrenergic Receptor Signaling and Binding ..............................................................3!
Beta-Adrenergic Receptors and Diabetes ............................................................................3!
Diabetes and the Retina .......................................................................................................5!
Diabetes in Heart, Lungs, and Kidneys ...............................................................................5!
Autonomic Nervous System Signaling: Adrenergic Receptors...........................................5!
Beta-Adrenergic Receptors: The Retina ..............................................................................6 
Hypotheses of Diabetic Retinopathy ...................................................................................6!
CHAPTER 3. COMPOUND 12: BETA-ADRENERGIC RECEPTOR 
SIGNALING BY THE ISOMERS OF ISOPROTERENOL AND LIKE DRUGS 
IN RETINAL ENDOTHELIAL CELLS AND MÜLLER CELLS.............................10!
Introduction........................................................................................................................10!
Compound Synthesis .........................................................................................................10!
Materials and Methods.......................................................................................................12!
Results................................................................................................................................12!
Discussion ..........................................................................................................................18!
Conclusion .........................................................................................................................18!
CHAPTER 4. COMPOUND 49B: A NOVEL BETA-ADRENERGIC 
RECEPTOR AGONIST IN THE TREATMENT OF DIABETIC 
RETINOPATHY..............................................................................................................19!
Introduction........................................................................................................................19!
Materials and Methods.......................................................................................................19!
Results................................................................................................................................24!
Discussion ..........................................................................................................................36!
CHAPTER 5. SUMMARY AND CONCUSIONS ........................................................43!
Correlations: Clinical and Non-Clinical Findings of Diabetic Retinopathy......................43!
The Novel Compound 49b.................................................................................................43!
Effects of Diabetes on Beta-Adrenergic Receptor Signaling ............................................43!
Advantages of Compound 49b over Isoproterenol ............................................................44!
Specific Findings of Compound 49b .................................................................................44!
Potential Mechanisms of Action for Compound 49b ........................................................45!
Limitations to the Compound 49b Study...........................................................................46!
Future Studies ....................................................................................................................46!
LIST OF REFERENCES................................................................................................48!
VITA .................................................................................................................................55!
 viii 
LIST OF TABLES 
 
Table 4-1.! Prevention Study Vital Measurements. .........................................................25!
Table 4-2.! Delayed Treatment Study Vital Measurements.............................................26!
 ix 
LIST OF FIGURES 
 
Figure 2-1.! Adrenergic Receptor Signaling.......................................................................4!
Figure 2-2.! Hypothesis of Diabetic Retinopathy. ..............................................................7!
Figure 3-1.! Chemical Structures of Isoproterenol. ..........................................................11!
Figure 3-2.! Chemical Structure of Xamoterol. ................................................................13!
Figure 3-3.! Cleaved Caspase 3 Results in REC for Compounds R-1, 10, 11, and 12.....14!
Figure 3-4.! TNF-! Activity Results in REC for Compounds 10 and 12. ........................15!
Figure 3-5.! Cleaved Caspase 3 Results in Müller Cells for Compounds R-1, S-1, 11, 
and 12. ..........................................................................................................16!
Figure 3-6.! TNF-! Activity Results in Müller Cells for Compounds R-1, S-1, 10, 11 
and 12. ..........................................................................................................17!
Figure 4-1.! Structure of Compound 49b..........................................................................20!
Figure 4-2.! Bar Graph of Cleaved Caspase 3 and TNF-! Protein Levels on Retinal 
Endothelial Cells. .........................................................................................27!
Figure 4-3.! PKA ELISA Results. ....................................................................................28!
Figure 4-4.! ERG Waveforms and Graphs after Compound 49b Treatment from the 
Prevention Group .........................................................................................30!
Figure 4-5.! ERG Waveforms and Graphs after Compound 49b Treatment from the 
Delayed Treatment Group............................................................................31!
Figure 4-6.! Results of Retinal Thickness and Ganglion Cell Layer Count. ....................32!
Figure 4-7.! Bar Graph of Acellular Capillaries per Millimeter Squared of Retinal 
Tissue and Pericyte Ghost Counts of Control (Ctrl), Diabetic, and 
Treatment Rats (Diab+49b). ........................................................................33!
Figure 4-8.! Results from Cleaved Caspase 3 ELISA on Retinal Lysates from Control 
(Ctrl), Diabetic, and Diabetic+Treatment Rats (Diab+49b). .......................34!
Figure 4-9.! Bar Graph of the Ratio of Phosphorylated Akt and Total Akt Protein 
Levels. ..........................................................................................................35!
Figure 4-10.!Bar Graph of the Ratio of Phosphorylated Insulin Receptor Beta (IRB) 
to Total Insulin Receptor Beta Protein Levels. ............................................37!
 x 
Figure 4-11.!Results from TNF-! ELISA on Retinal Lysates from Control (Ctrl), 
Diabetic, and Diabetic+Treatment Rats (Diab+49b). ..................................38!
Figure 4-12.!Bar Graph of the Ratio of Phosphorylated and Total Insulin Receptor 
Substrate-1 Protein Levels. ..........................................................................39!
Figure 4-13.!Heart Images from Control, Diabetic, and Diabetic+Compound 49b 
Rats...............................................................................................................40!
 
  1 
CHAPTER 1.    INTRODUCTION 
 
 
Diabetic retinopathy has been shown to be the leading cause of blindness in 
working Americans (Frank 2004).  Complications of the disease include inflammatory 
cytokine up-regulation (Kowluru & Odenbach 2004), TNF-! mediated apoptosis 
(Joussen et al 2009), neuronal and vascular changes, pericyte loss, basement membrane 
thickening, and neovascularization (Wiley et al 2005).  Present therapy for diabetic 
retinopathy includes vitrectomy and laser photocoagulation therapy.  These therapies are 
highly effective clinically, however side effects from both procedures have risks, such as 
some permanent vision loss and retinal detachment (Chew et al 2003).  Therefore, we 
began to hypothesize and investigate a potential mechanism by which reduction of retinal 
changes induced by diabetes could be accomplished. 
 
Early in vivo work in our lab showed that after surgical sympathectomy retinal 
and choroidal changes were seen in the eye (Steinle 2003) and these changes were similar 
to diabetes-induced changes in the eye, including basement membrane thickness and 
pericyte ghost formation.  In addition, previous work in our lab also showed that in vitro 
stimulation with propranolol, a beta-adrenergic receptor antagonist, caused similar 
changes as those seen after surgical sympathectomy while the alpha-adrenergic receptor 
antagonist, phentolamine, produced no changes (Steinle 2002).  Because treatment with 
propranolol caused changes that were similar to sympathectomy, and stimulation with the 
alpha-adrenergic receptor antagonist showed no changes, we hypothesized that 
stimulation with a beta-adrenergic receptor agonist may prevent retinal changes induced 
by diabetes.  Further work investigating beta-adrenergic receptor stimulation showed that 
apoptotic (Williams et al 2009) and inflammatory markers (Steinle et al 2007) were 
reduced significantly in vitro.   
 
It was possible that surgical ganglionectomy could cause the biochemical, 
vascular, and neuronal changes as seen in diabetic retinopathy (Frank 2004) and to 
determine this, a genetic model was used.  The dopamine beta-hydroxylase knock-out 
(DBH-KO) model was used because it was previously shown that decreased 
norepinephrine levels were consistent with detrimental retinal manifestations (Jandrastis 
et al 2002).  We found that in the absence of dopamine beta-hydroxylase, similar 
biochemical, vascular, and neuronal changes occurred in the retina as seen post 
sympathectomy (Panjala et al 2010).  After reviewing these findings, we hypothesized 
that restoration of beta-adrenergic receptor signaling may improve retinal changes 
associated with diabetic retinopathy; specifically that beta-receptor stimulation could 
possibly modulate changes in the retina induced by diabetes. 
 
This thesis introduces a novel, beta-adrenergic receptor agonist, Compound 49b, 
whose treatment has shown to significantly reduce markers of diabetic retinopathy more 
effectively than similar beta-adrenergic receptor agonist compounds tested.  In addition to 
in vitro and in vivo experimentation, we also hypothesized the potential signaling 
mechanism by which Compound 49b exerts its actions, and carried out non-invasive 
functional testing to gain more insight on the influence compound administration had on 
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the retina and internal homeostasis.  Collectively, these findings may contribute to 
understanding the progression of diabetic retinopathy and the novel compound presented 
here may be a possible therapeutic intervention for treatment of the disease. 
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CHAPTER 2.    LITERATURE REVIEW 
 
  
 This Review of the Literature of diabetic retinopathy and its retinal complications 
consists of topics beginning with diabetes and how it effects organs and beta-adrenergic 
signaling, leading up to our hypotheses on signaling mechanism involved in the 
progression of diabetic retinopathy.  This chapter includes a detailed discussion with 
literary findings, supporting our hypotheses and theory behind Compound 49b actions. 
 
 
Beta-Adrenergic Receptor Signaling and Binding 
 
 Beta and alpha-adrenergic receptors belong to a very large family of hormone 
receptors (Joost et al 2002), which are linked with guanine nucleotide-binding regulatory 
proteins (G-proteins), Gs and Gi among others, and together are commonly known as 
G-protein coupled receptors (GPCR) (Chen-Izu et al 2000).  Gs is the stimulatory subunit 
of the receptor and Gi is the inhibitory subunit of the receptor (Wettschureck & 
Offermanns 2005).  The majority of GPCRs share a common structural motif consisting 
of seven trans membrane helices (Ghanouni et al 2001).  Once an agonist binds to the 
adrenergic receptor, the GPCR undergoes a conformational change and initiates 
intracellular signaling events (Bortolato et al 2009).  
 
 Adrenergic receptors can be divided in to two main groups, alpha and beta, with 
several subtypes (Chen-Izu et al 2000) (Figure 2-1).  Alpha-receptor subtypes include A1 
and A2 and beta--receptors subtypes include B1, B2, and B3 (Sagrada et al 1987).  It is 
generally assumed that once an agonist binds to the beta-receptor, the receptor-associated 
G-protein is activated (Vassilatis et al 2003) and stimulates adenylyl cyclase to make 
cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A 
(PKA) and activates other downstream signaling molecules.  In contrast, alpha receptors 
activate phospholipase C (A1 receptors) or inactivate adenylyl cyclase (A2 receptors) 
(Schmitz et al 1981).   
 
 
Beta-Adrenergic Receptors and Diabetes 
 
Diabetes is the result of the body’s inability to produce insulin, as in type I 
diabetes mellitus, or the body’s inability to properly use insulin, as in type II diabetes 
mellitus (Wild et al 2004).  Insulin is an important hormone and signaling molecule 
involved with diabetes (Steiner & Oyer 1967) and its normal function is critical to 
maintenance of homeostasis and in treatment of the disease.  While literature suggests 
that there may be crosstalk between the insulin receptor and the GPCR in pancreatic 
cancer cells (Walker 2007), crosstalk has not been characterized in the retina.  These 
findings suggest that the beta-adrenergic receptor may be a target in regulation of the 
complications of diabetes in the retina. 
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Figure 2-1. Adrenergic Receptor Signaling. 
Giubergia, V.,  Zelazko, M., Roy, A., Gravina, L.P., Pena, H.G.,  & Chertkoff, L. (2009). 
Beta-2 AR polymorphism (homozygous arginine 16) associated with higher IgE in 
children with asthma.  Asth and Immunol., 102, (4), 308-313. Reprinted with permission. 
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Diabetes and the Retina 
 
 The damage to the retina is characteristic of diabetic retinopathy, the leading 
cause of blindness in working adults (Frank 2004).  Long-term complications of diabetes 
can induce changes to the retina such as increased retinal thickness due to accumulation 
of fluid in the macula (Aiello 1998).  In diabetic retinopathy, elevated glucose induces 
pericyte cell death (Ejaz et al 2008), the cells which support endothelial cells in retinal 
blood vessels, and thickening of the basement membranes of these vessels (Pardianto 
2005), producing incompetent and permeable blood vessels.  Clinical manifestations of 
non-proliferative retinopathy include retinal bleeding (Davis et al 1998), venous beading, 
or intraretinal microvascular anomalies (IRMA) (Flynn & Tooke 1992).  The progression 
from the non-proliferative stage to the proliferative stage is due to a reduction in oxygen 
inducing proliferation of faulty blood vessels in the retina.  The proliferative stage of 
diabetic is indicative of new blood vessels on the surface of the optic nerve head, known 
as neovascularization of the disc (NVD) or the retina itself, known as neovascularization 
elsewhere (NVE) (Davis et al 1998; Sharma & Chandrarajan 2004).  While laser and 
panretinal photocoagulation have shown been to slow progression of blindness in the 
disease (Fraser-Bell et al 2008), novel therapies are still needed, due to side effects 
presented earlier which are associated with current therapies. 
 
 
Diabetes in Heart, Lungs, and Kidneys 
 
 Diabetes has been shown to induce cardiac dysfunction, more specifically, 
diabetic cardiomyopathy.  Diabetic cardiomyopathy is characterized functionally by 
ventricular dysfunction (Avogaro 2003), myocyte hypertrophy, interstitial fibrosis (Wang 
et al 2006), and decreased systolic function in the presence of a diastolic dysfunction.  
More specifically with the heart, intravenous administration of isoproterenol induces left 
ventricular hypertrophy (Udelson et al 1989).  While little correlations have been made 
between diabetes and its effect on the lungs, it is important to reference the lungs in this 
thesis because of the abundant expression of beta-adrenergic receptors (Frishman 2003). 
 
 Desensitization of beta-adrenergic receptors in the lung can induce lung injury 
(Kabir et al 2009).  Diabetes also affects the kidney producing diabetic nephropathy or 
Kimmelstiel-Wilson syndrome (Berkman & Rifkin 1973), which is characterized by 
angiopathy of capillaries in the kidney glomeruli, leading to kidney dysfunction.  
Diabetes affects the body in numerous detrimental ways and affects other systems in the 
body, importantly the nervous system. 
 
 
Autonomic Nervous System Signaling: Adrenergic Receptors 
 
 The autonomic nervous system, a part of the peripheral nervous system, is 
composed of two subsystems, parasympathetic and sympathetic nervous systems (Grub et 
al 1999).  Diabetes can induce autonomic neuropathy.  In this disease, nerves are 
damaged producing altered blood pressure, heart rate, and digestion (Benarroch et al 
  6 
1993). In diabetic neuropathy, there is a reduction of motor and sensory nerve conduction 
(Ferrnyhough & Schmidt 2002) resulting in reduced blood flow to the limbs.  The 
constant firing of nerves in the limb causes tingling in their limbs and eventually loss of 
total function and possibly amputation due to decreased or no blood flow (Said 2007).  
 
 In the eye, the sympathetic nerves have been shown to influence retinal function 
and diabetic retinopathy (Steinle & Smith 2002; Wiley et al 2005).  In the past, it was 
believed that sympathetic nerves do not innervate the retina (Laties 1966); however, it 
was later shown that sympathetic nerves do innervate the retina (Furukawa 1987).  It was 
also shown that stimulation of beta-adrenergic receptors on endothelial cells increases 
cAMP production (Daniel et al 1987).  Further, Burnstock et al (1990) revealed that 
sympathetic nerves were altered in diabetes.  Following this, Wiley et al (2005) showed 
that loss of sympathetic nerves influenced basement membrane thickness and induced 
pericyte loss, both complications of diabetic retinopathy.  These data findings suggest 
that beta-receptor stimulation in the retina may slow the progression of diabetic 
retinopathy.  
  
Since then, the influence of beta-adrenergic receptor stimulation on diabetic 
retinopathy has and is still being investigated in our lab.   Specifically, stimulation of 
beta-adrenergic receptors on Müller and retinal endothelial cells (REC) with Compound 
49b resulted in the down regulation of vascular and neuronal markers of diabetic 
retinopathy and restoration of normal beta-adrenergic receptor signaling (data in 
submission). 
 
 
Beta-Adrenergic Receptors: The Retina 
 
Current studies in our lab have shown that Müller cells possess B1 
(Walker & Steinle 2007) and B2-adrenergic receptors subtypes, while REC possess B1 
and B3-adrenergic receptor subtypes (Steinle & Smith 2002).  Stimulation of the 
beta-adrenergic receptors on the above-mentioned cell types elicited beneficial effects in 
the retina, such as reductions in inflammatory and apoptotic markers. 
 
 
Hypotheses of Diabetic Retinopathy 
 
Data has shown that beta-adrenergic receptor stimulation may be beneficial to the 
retina (Walker & Steinle 2007; Williams & Steinle 2009), however the exact mechanism 
by which this occurs is not well known.  To generate a possible treatment for diabetic 
retinopathy, it was necessary to understand the cellular signaling mechanism by which a 
beta-adrenergic receptor agonist modulates components of the disease.  There are 
numerous biochemical mechanisms that can help explain the progression of diabetic 
retinopathy (Figure 2-2), which include inflammation, reactive oxygen species formation, 
apoptotic death of retinal cells, and altered insulin production (Klein et al 1995).   
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Figure 2-2. Hypothesis of Diabetic Retinopathy. 
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As stated previously, activation of the beta-adrenergic receptor induces activation 
of PKA, which in turn activates downstream signaling molecules (Vassilatis et al 2003). 
 
It is well understood that in diabetes insulin production is reduced.  In the beta 
cell of the pancreas, activation of PKA triggers insulin secretion (Gao et al 2002).  It also 
has been shown that insulin signaling is up-regulated post stimulation with isoproterenol, 
a non-selective beta-adrenergic receptor agonist (Jiang et al 2010).  Specifically, 
isoproterenol was shown to increase insulin receptor substrate-1 (IRS-1), which in turn 
activates Akt, and reduces cleavage of caspase 3.  Insulin signaling is however inhibited 
at IRS-1 in the presence of TNF-!, an inflammatory marker (van den Oever et al 2010).  
TNF-! activation, in addition to altering insulin signaling, is also involved in apoptosis in 
the retina. 
 
The inflammatory component of diabetic retinopathy is a result of increased 
production of inflammatory markers.  Specifically, TNF-! and interleukin beta (IL-1B) 
are up regulated in the disease state (Chen et al 2005).  IL-1B is a pro-inflammatory 
marker, which mediates TNF-! activation (Kamangar et al 2006).  Multiple cell types in 
the body, such as mast cells, neuronal tissue, and endothelial cells, produce TNF-! 
(Delair et al 2009).  TNF-! has been shown to induce apoptotic cell death and 
inflammation (Locksley et al 2001).  TNF-! binds to the tumor necrosis factor-receptor 
(TNFR), and induces cleavage of caspase 3,8, leading to cell death.  Because TNF-! 
increases insulin resistance (Kamangar et al 2006), leading to a decrease in Akt, it is 
necessary to investigate production of TNF-! in these studies. 
 
Increased oxidative stress is widely accepted as an underlying factor in the 
progression and development of the complications associated of diabetic retinopathy 
(Maritim et al 2002).  Glucose oxidation results in the formation of reactive oxygen 
species, mainly peroxynitrite radicals formed after superoxide radicals interact with nitric 
oxide.  Free radicals can also be formed via formation of advanced-glycation end 
products (AGEs) (Cusick et al 2002).  AGEs-induced reactive oxygen species formation 
also activates NF-kB (nuclear factor kappa-light chain-enhancer of activated B cells), a 
transcriptional factor that enhances nitric oxide formation (Ziyun et al 2007; Kim et al 
2010).  The constitutive NF-kB also regulates anti-apoptotic genes and inhibition of 
NF-kB has been shown to induce cellular apoptosis (Kim et al 2010). Contrastingly, 
NF-kB also regulates pro-inflammatory gene expression and synthesis of cytokines such 
as TNF-! and IL-1B and therefore possesses pro-apoptotic properties as well (Tak and 
Firestein 2001). 
 
As stated, apoptosis is also a component of diabetic retinopathy and it is likely the 
final step in disease progression at the cellular level.  Apoptosis of key retinal cells can 
lead to cell loss in the retina and blindness. One important family of cysteine proteases, 
the caspase family, plays an essential role in cell death or apoptosis (Lavrik et al 2005). 
This family of proteases exists in the pro-form, and is regulated post-transcriptionally.  
There are many key proteins that are involved in apoptosis such as cytochrome c and 
Bcl-2, which activate caspase 9, and Fas (van den Oever et al 2010).  It has been reported 
that diabetes induces apoptosis in the eye via caspase 3 activation (Mohr et al 2002).  It 
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has also been shown that retinal ganglion cells express apoptotic factors such as Fas, Bax, 
and cytochrome C (Abu El-Asrar et al 2007). Furthermore, it has been shown that 
treatment with xamoterol, a beta-1 selective agonist, on retinal endothelial cells signals 
through the Fas ligand pathway to regulate apoptosis (Williams & Steinle 2009).  The 
above listed factors promote apoptosis and inhibition of these factors may prevent 
apoptosis, a major contributing factor to progression as a result of diabetic retinopathy. 
 
Continuing our knowledge on beta-adrenergic receptor effects in the retina and 
potential causes of diabetic retinopathy, we hypothesize that treatment with a 
beta-adrenergic receptor agonist could prevent changes associated with diabetic 
retinopathy.  By screening various compounds synthesized in-house, we evaluated their 
ability to reduce changes associated with the disease.  The subsequent chapters present 
two compounds, which were effective at reducing markers of diabetic retinopathy in the 
rat model, in vivo, and in cell culture, in vitro. 
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CHAPTER 3.    COMPOUND 12: BETA-ADRENERGIC RECEPTOR 
SIGNALING BY THE ISOMERS OF ISOPROTERENOL AND LIKE DRUGS 
IN RETINAL ENDOTHELIAL CELLS AND MÜLLER CELLS 
 
 
Introduction 
 
 Thickening of the basement membrane of the capillaries in the retina, loss of 
pericytes, and formation of microaneurysms characterize diabetic retinopathy (Frank 
2004).  Although laser photocoagulation surgery is the primary treatment of the disease, 
the associated risks including peripheral vision loss and cataract formation (Abu El-Asrar 
et al 2007) impose a need for additional therapeutic options.  Müller cells and REC are 
involved in the pathogenesis of diabetic retinopathy.  Müller cells serve as supporting 
glial cells of the retina, and REC are decreased as the disease progresses, ultimately 
leading to blindness (Williams & Steinle 2009).  
 
 We have previously shown that the loss of sympathetic neurotransmission leads to 
increased inflammatory marker levels and apoptosis of photoreceptors (Steinle 2007).  
We have also demonstrated that retinal Müller cells possess both beta-1 and beta-2-
adrenergic receptors (Williams & Steinle 2009), while retinal endothelial cells possess 
beta-1 and beta-3-adrenergic receptors (Walker & Steinle 2007). Our results showed that 
treatment with 10uM isoproterenol, a non-selective beta-adrenergic receptor agonist or 
10uM xamoterol, a selective beta-adrenergic receptor agonist on Müller and REC cells 
reduced apoptosis in both cell types via a reduction of cleaved caspase 3 levels in vitro 
(Walker & Steinle 2007; Williams & Steinle 2009).  Because diabetic retinopathy has 
characteristics of inflammation (Joussen et al 2009), we have data indicating that TNF-! 
levels were reduced after isoproterenol treatment over an 8-month period (Jiang et al 
2010).  However, isoproterenol produced remodeling of the left ventricle when 
administered topically in the eye, demonstrating negative responses of systemic exposure 
(Heather et al 2009).  We sought to develop novel derivatives of isoproterenol and to 
evaluate their ability to reduce the cleavage of caspase 3 (a marker of apoptosis) and 
TNF-! levels (a marker of inflammation) in the retina.  Isoproterenol has one asymmetric 
center and exists as enantiomers (Figure 3-1). 
 
 Although the two optically active enantiomers have same achiral physical 
properties in general, discrepancies in physiological activities are quite often observed 
between the two enantiomers.  Therefore, the development of a single enantiomeric 
compound instead of racemic mixtures is strongly encouraged in new drug development. 
 
 
Compound Synthesis 
 
 In collaboration with Dr. Duane Miller, our chemist Jayaprakash Pagadala, 
enantioselective synthesis of catecholamines was carried out by using the Sharpless 
asymmetric dihydroxylation.  We observed S-1 to be significantly less potent than the  
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Figure 3-1. Chemical Structures of Isoproterenol. 
From left to right: Racemic isoproterenol, R-1 isomer of isoproterenol, and S-1 isomer of 
isoproterenol corresponding R-1 after statistical analyses. Compounds were then 
synthesized with the chemical backbone of the R-1 isomer. 
.
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corresponding R-1 after statistical analyses.  Compounds were then synthesized with the 
chemical backbone of the R-1 isomer. 
 
 
Materials and Methods 
  
 REC were purchased from Cell Systems Corporation (CSC) (Kirkland, WA) and 
cultured in CSC medium grown in high glucose (25 mM).  Media was supplemented with 
20% fetal bovine serum (FBS) and antibiotics.  Müller cells were kindly provided by Dr. 
Vijay Sarthy, Northwestern University) were cultured in high glucose (25 mM) in 
Dulbecco’s Modified Eagle’s Medium (DMEM) and supplemented with 10% FBS and 
antibiotics.  Twenty-four hours before treatment with compounds R-1, S-1, 10, 11, and 
12, Müller cells and REC were cultured in high glucose medium with antibiotics and 0% 
FBS to induce serum starvation. 
 
 Dishes of each cell type were cultured in only high glucose to serve as non-treated 
controls. Dishes from each cell type for each dosage were cultured in high glucose and 
treated with 50nM, 100nM, and 10uM dosages of each of the 5 compounds.  REC were 
treated for 30- and 60-minutes, while Müller cells were treated for1-and 24-hours.  REC 
time points were based upon data with xamoterol (Figure 3-2), which was shown to be 
most effective at reducing apoptotic markers after 30-and 60-minutes of stimulation 
(Williams & Steinle 2009).  Müller cell time points were based upon data with 
isoproterenol (Walker & Steinle 2007).  Retinal lysates from Müller and REC were 
assayed using a human TNF-! ELISA assay (Thermo Scientific) (Rockford, IL) and 
cleaved caspase 3 ELISA kit (Cell Signaling) (Danvers, MA). 
 
 
Results 
 
Apoptosis of REC is a factor in the early phases of diabetic retinopathy. 
Therefore, we used decreased cleavage of caspase 3 as a marker of reduced apoptosis in 
cells cultured in high glucose.  Compounds R-1, 11, and 12 significantly decreased 
caspase 3 levels in REC (Figure 3-3), while 10 and S-1 did not significantly decrease 
caspase 3 levels after treatment.  Compound 12 significantly reduced caspase 3 levels at 
the 50nM and 100nM dosages within the 30-and 60-minute time points, which is lower 
than isoproterenol.  To evaluate inflammatory marker levels in culture, TNF-! levels 
were evaluated.  We found that Compound 12 decreased both TNF-! and caspase 3 levels 
in REC while Compound 10 increased TNF-! levels (Figure 3-4).  TNF-! levels in REC 
were unchanged after treatment with R-1, S-1, and Compound 11 (not shown).  On the 
other hand, cleaved caspase 3 levels in Müller cells (Figure 3-5) were not significantly 
decreased after treatment with R-1, S-1, 10, 11, or 12.  The non-specific beta-adrenergic 
receptor agonist R-1 and S-1 isomers decreased TNF-! inflammatory levels in Müller 
cells (Figure 3-6), consistent with preliminary results from isoproterenol; however, R-1 
decreased TNF-! at the 50nM and 100nM dosages, which is lower than the effective dose 
of isoproterenol.  All analogs failed to significantly decrease TNF-! in Müller cells. 
Based upon these results, Compound 12 decreased both markers in REC only.  
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Figure 3-2. Chemical Structure of Xamoterol. 
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Figure 3-3. Cleaved Caspase 3 Results in REC for Compounds R-1, 10, 11, and 
12. 
Graphs show results of caspase 3 ELISA. For isomers of isoproterenol, cells were treated 
at 10uM at 15-, 30-, and 45-minutes. Analogue compounds 10,11, and 12 were treated at 
50nM, 100nM, and 10uM at 30-minutes and 1-hour time points. Treatment groups were 
compared to not-treated (NT) controls. *P<0.05 vs. NT. 
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Figure 3-4. TNF-! Activity Results in REC for Compounds 10 and 12.  
Analogue compounds 10 and 12 were treated at 50nM, 100nM, and 10µM at 30-minutes 
and 1-hour time points. Treatment groups were compared to not-treated (NT) controls. 
*P<0.05 vs. NT. 
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Figure 3-5. Cleaved Caspase 3 Results in Müller Cells for Compounds R-1, S-1, 
11, and 12.   
Compounds R-1, S-1, 11 and 12 were treated at 50nM, 100nM, and 10uM at 1-and 24- 
hour time points.  Treatment groups were compared to not-treated (NT) controls.  
*P<0.05 vs. NT. 
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Figure 3-6. TNF-! Activity Results in Müller Cells for Compounds R-1, S-1, 10, 
11 and 12.   
Analogue compounds R-1, S-1, 10, 11, and 12 were treated at 50nM, 100nM, and 10uM 
at 1- and 24-hour time points.  Treatment groups were compared to not-treated (NT) 
controls.  *P<0.05 vs. NT. 
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Discussion 
Screening of our novel compounds showed diverse receptor activity between REC 
and Müller cells.  Preliminary experiments with isoproterenol showed it to be effective at 
reducing caspase 3 in both cell types and TNF-! in REC (Williams & Steinle 2009). We 
observed that R-1 significantly reduced caspase 3 levels in REC and in Müller cells, 
while S-1 did not affect caspase 3 or TNF-! activity in REC.  S-1 did show a decrease in 
TNF-! activity in Müller cells but R-1 was observed to be more effective, as it decreased 
TNF-! levels at lower dosages.  Identifying the R-isomer as the more active enantiomer 
of isoproterenol allowed for formulation of more specific derivatives of the R-isomer. 
 
We reported that xamoterol, a selective beta-1-adrenergic receptor agonist, was 
able to significantly reduce caspase 3 and TNF-! levels in REC (Williams & Steinle 
2009).  We also reported that beta-2 adrenergic receptor selectivity needed to be 
maintained to stimulate Müller cells (Walker & Steinle 2007).  We hypothesized that the 
morpholine moiety accounts for xamoterol’s high selectivity for beta-1 adrenergic 
receptors, and we therefore designed structural catecholamine derivatives of isoproterenol 
and attached the morpholine moiety to test the ability of these analogues to reduce 
cleavage of caspase 3 and TNF-! activity.  The structural analogues, compounds 10, 11, 
and 12 had various effects in both cell types.  We observed that Compound 10 were not 
able to significantly decrease caspase 3 cleavage or TNF-! in REC or Müller cells.  
Compound 11 was able to decrease cleaved caspase 3 levels in REC but was not effective 
in Müller cells, while 12 was able to decrease both caspase 3 and TNF-! in REC. 
Compound 12 effectively decreased both inflammatory and apoptotic levels in REC and a 
significant decrease was not observed in Müller cells.  These findings suggested that 
continued synthesis of isoproterenol analogues could present new drug candidates able to 
reduce apoptotic and inflammatory markers, making them useful therapeutic agents in the 
treatment of diabetic retinopathy. 
 
 
Conclusion 
 
We have shown that single enantiomer R-1 is more potent than the S-1enantiomer 
of isoproterenol.  Due to its effectiveness over S-1, the analogues of R-1 were formulated 
and Compound 12 was the only analogue that significantly decreased both apoptotic and 
inflammatory levels in REC cells.  In addition to the findings on 12, the data using R-1 
also suggests that there is a separation of the responsiveness to specific classes of 
beta-adrenergic receptors.  REC possess beta-1 and beta-3 adrenergic receptors, while 
Müller cells possess beta-1 and beta-2-adrenergic receptors, where the beta-1 and beta-2 
adrenergic receptor is the dominant type.  These findings suggest that Compound 12 is 
the most effective analogue in its ability to decrease both inflammatory and apoptotic 
levels in vitro using REC.  This decrease was observed at a lower dosage than the 
effective dose of isoproterenol and it did not bind to beta-adrenergic receptors, which 
indicates a different mechanism for Compound 12 as compared. 
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CHAPTER 4.    COMPOUND 49B: A NOVEL BETA-ADRENERGIC RECEPTOR 
AGONIST IN THE TREATMENT OF DIABETIC RETINOPATHY 
 
 
 Although Compound 12 was found to be effective in REC, we sought to screen 
more beta-adrenergic receptor agonists due to the inability of Compound 12 to effectively 
prevent high-glucose induced changes in Müller cells.  Compounds were analyzed using 
ELISA assays for their ability to reduce TNF-! and caspase 3 in REC and Müller cells. 
Data obtained from these screenings showed that of the compounds tested, Compound 
49b effectively prevented and delayed the onset of changes associated with diabetic 
retinopathy. 
 
 
Introduction 
 
Data in the field has shown that diabetic retinopathy is the leading cause of 
blindness in American adults (Frank 2004).  Some of the changes noted in early diabetic 
retinopathy include thickening of the basement membrane, pericyte loss, degenerate 
capillary formation, and the loss of cell number in the ganglion cell layer of the retina 
(Wiley et al 2005).  In addition to retinal changes common to diabetes, sympathetic 
nerves are also damaged following chronic hyperglycemia (Burnstock 1990). Work in the 
dopamine beta hydroxylase knockout mice demonstrated that loss of norepinephrine 
produced retinal changes similar to those noted in diabetic retinopathy (Steinle et al 
2009).  This finding suggests that maintenance of adrenergic receptor signaling may be 
beneficial to the retina and prevent neuronal and vascular damage.  Indeed, previous 
work in our lab has shown that daily administration of 50mM marker levels, as well as 
the histological changes in the diabetic retina (Jiang et al 2010).  Isoproterenol also 
maintained normal electrical activity of the retina, while increasing Akt and insulin 
receptor phosphorylation in diabetic rats compared to control values.  Unfortunately, 
previous studies also showed that 50mM topical isoproterenol led to increased systemic 
circulation of the drug, which induced detrimental cardiovascular remodeling.  We 
therefore developed a novel beta-adrenergic receptor agonist, Compound 49b (Figure 
4-1) to evaluate its ability to reduce markers of diabetic retinopathy without causing 
cardiovascular remodeling. 
 
 
Materials and Methods 
 
We have previously demonstrated that isoproterenol can prevent the neuronal and 
vascular changes in the diabetic rat retina (Jiang et al 2010).  While isoproterenol was a 
potent beta-adrenergic receptor agonist, topical administration caused left ventricular 
remodeling, suggesting that isoproterenol enters into the systemic circulation.  To avoid 
these deleterious side effects, we synthesized Compound 49b to mimic the structure of 
isoproterenol.  Compound 49b has both beta-1 and beta-2 adrenergic receptor specificity 
but also has a trimethyl group opposite the catechol.  
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Figure 4-1. Structure of Compound 49b. 
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 Structurally, Compound 49b consists of an N-substituent p-methoxyphenyl ring, 
which allows "-" electron interactions with the catechol aromatic ring to lock in the 
conformation.  The stability of this conformation limits the conformational and 
orientational freedom within the beta-adrenergic receptor-binding pocket.  These 
conformational interactions increase the activity of Compound 49b in comparison to 
isoproterenol. 
 
REC were purchased from Cell Systems Corporation (CSC) (Kirkland, WA) and 
maintained in CSC media supplemented with 20% FBS and antibiotics. Only primary 
cells between passages 2-4 were used for all experiments.  Cells were grown in high 
glucose medium (25mM) and once cells reached ~80% confluency, they were placed into 
high glucose medium without FBS to induce serum starvation for 18-24 hours.  Previous 
data suggested that treatment with beta-adrenergic receptor agonists for 30- and 
60-minutes produced a significant response to both cleaved caspase 3 and TNF-! level 
analyses (Williams & Steinle 2009), thus these time points were used for studies. Cells 
were treated with Compound 49b at the 50nM, 100nM, and 10uM dosages for 30- and 
60-minutes.  For all experiments, non-treated cells served as controls. 
 
 Müller cells were kindly provided by Dr. Vijay Sarthy (Northwestern University) 
were thawed and cultured in DMEM medium in high glucose (25mM) conditions.  
Medium was supplemented with 10% FBS and antibiotics.  Once cells reached ~ 80% 
confluency, they were placed into high glucose medium without FBS to induced serum 
starvation for 18-24 hours.  Müller cells were treated with Compound 49b at the 1-and 
24-hour time points following serum starvation.  For consistency with the REC data, 
Müller cells were treated at 50nM, 100nM, and 10uM for all compounds.  For all 
experiments, some cells remained untreated as controls. 
 
 To screen the ability of Compound 49b to reduce the of cleavage of caspase 3 and 
TNF-! levels in vitro, cleaved caspase 3 ELISA assay (Cell Signaling) (Danvers, MA) 
and TNF-! ELISA assay (Thermo Scientific) (Rockford, IL) analyses were carried out 
according to the manufacturer’s protocol, except that equal protein amounts were loaded 
into each well to allow for calculations using optical density values.  Both REC and 
Müller cells were treated with each compound at the same dosages and time points.  All 
analyses were done and compared to non-treated controls. 
 
To determine the optimal dose in vivo in diabetic rats, male Lewis rats 
were purchased from Charles River at 8-weeks of age.  To induce diabetes, a single 
injection of 60mg/kg streptozotocin dissolved in citrate buffer (Fisher Scientific) 
(Pittsburgh, PA) was administered.  Control rats were injected with citrate buffer only.  
Rat glucose levels were tested 2 days following the injection, with glucose levels 
>250mg/dL accepted as diabetic.  To determine whether topical application of Compound 
49b reaches the retina and elicits a response common to beta-adrenergic receptor 
stimulation, multiple doses of Compound 49b were analyzed for their ability to increase 
PKA activity in the diabetic rat retina.  Two groups of animals were used: a non-diabetic 
control group (Ctrl) and a diabetic + treatment group (Diab+49b).  Diabetes was induced 
for 2 months prior to any treatments.  Animals in both groups were treated with 7 
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different doses of Compound 49b (all below the required dose of 50mM for 
isoproterenol): 1uM, 10uM, 100uM, 1mM, 5mM, 10mM, and 20mM.  After 4-days of 
topical Compound 49b treatment, animals were anesthetized with ketamine-xylazine 
cocktail.  Retinal lysates from rats in all groups were analyzed using a PKA Activity 
ELISA (MesaCup PKA Activity ELISA) (Temecula, CA) to quantitate the activation of 
PKA following Compound 49b stimulation, which would suggest that topical Compound 
49b reached the retina and elicited a physiological beta-adrenergic receptor stimulation 
response. 
 
 Male Lewis rats were purchased from Charles River at 8 weeks of age.  Three 
groups of rats were used for each of the prevention and delayed treatment groups: 
non-diabetic (Ctrl), diabetic, and diabetic+49b (Diab+49b).  Rats receiving immediate 
eye drop therapy were injected with streptozotocin and after one week of injection, rats 
were characterized as having diabetes once glucose levels were >250 mg/dL.  Diabetic 
+Compound 49b rats began receiving daily topical drops of 1mM Compound 49b on the 
day glucose levels were measured to be above 250mg/dL.  Diabetic only and control rats 
received no Compound 49b. 
 
 Another subset of treatment rats were injected and characterized in the same 
manner as the prevention group, but treatment with 1mM topical 49b began after rats had 
untreated diabetes for 6-months.  All rats in both groups received monthly ERG, blood 
pressure, intraocular pressure (IOP), and blood glucose and weight measurements.  Rats 
were sacrificed at 2- and 8- months of treatment in the prevention group and after 2- and 
6-months of treatment in the delayed treatment group.  All animal procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Tennessee Health Science Center and conform to all guidelines set forth by 
NIH.  Electroretinogram (ERG) analyses were carried out to evaluate the changes in the 
electrical activity of the retina as we have done previously (Jiang et al 2010).  Briefly, 
rats were dark adapted overnight.  ERG responses were recorded from both eyes together 
using platinum wire corneal electrodes, forehead reference electrode, and ground 
electrode in the tail.  Pupils were fully dilated using 1% tropicamide solution (Alcon) 
(Fort Worth, TX). Methylcellulose (Celluvise, Allergan) (Irvine, CA) drops were applied 
as well to maintain a good electrical connection and body temperature was maintained at 
37°C by a water-based heating pad.  ERG waveforms were recorded with a bandwidth of 
0.3-500Hz and samples at 2kHz by a digital acquisition system and were analyzed a 
custom-built MatLab program.  Statistics was done on the mean ±SD amplitudes of the  
a- and b- wave of each treatment group. 
 
 Blood pressure (BP) was measured noninvasively monthly using a CODA 
non-invasive blood pressure machine (CODA  Systems,Kent Scientific) (Torrington, 
CT). Animals were placed on an electrical heated pad and an individual holder consisting 
of an occlusion cuff and volume pressure recording (VPR) cuff was placed at the base of 
the tail, allowing systolic BP, diastolic BP, mean BP, heart pulse rate, tail blood volume, 
and tail blood flow to be measured simultaneously. 
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IOP was measured monthly using a tonometer (TonoLab, Colonial Medical 
Supply) (Franconia, NH).  Briefly, the tip of the probe of the tonometer was placed at the 
cornea of the eye.  During measurements, the tip of the probe contacts the cornea six 
times and gave the IOP reading of that eye.  This procedure was carried out in both eyes. 
Paraffin embedded sections of the retina were stained with toluidine blue for light 
microscopy and morphometry of retinal thickness as described (Jiang et al 2010). 
Photomicrographs were assessed for retinal thickness and the number of cells in the GCL 
was counted using methods previously described (Jiang et al 2010).  The thickness of the 
retina and the cell count were measured using OpenLab software (Improvision) 
(Lexington, MA). 
 
 Retinas from 1 eye of all control, diabetic, and diabetic+49b rats after 8-months (8 
months of diabetes) or 6 -months of treatment (12 months of diabetes) were used to count 
degenerate capillaries in prevention and delayed treatment groups, respectively.  The eyes 
were enucleated, suspended in 10% buffered formalin for 5 days, and the retina was 
dissected in 3% crude trypsin solution (Difco Bacto Trypsin 250) (Detroit, MI).  The 
retinal vascular tree was dried onto a glass slide and stained with hematoxylin-periodic 
acid-Shiff.  Degenerate capillaries were counted and identified as previously described 
(Jiang et al 2010).  Pericyte ghosts are estimated from the prevalence of spaces in the 
capillary basement membranes, where pericytes have disappeared.  Pericyte ghost 
numbers were determined in multiple mid-retina fields, and reported per 1000 capillary 
cells (Engerman & Kern 1994; Kern & Engerman 1995). 
 
 Tissue sections from the heart of control, diabetic, and treated rats at the 8-month 
of diabetes time point in the prevention treatment groups were analyzed for left ventricle 
morphology.  Tissue was frozen with freezing medium and 20um sections were obtained 
via cryostat sectioning.  Sections were fixed to glass slides and stained with Pico Red 
collagen stain.  Pictures were taken at 400x using a Retiga camera attached to a Nikon 
Biophot light microscope with Qcapture software (QImaging) (Canada). 
 
 Retinal lysates from one eye of all rats were assayed for protein levels of TNF-! 
(Thermo Scientific) (Rockford, IL) and cleaved caspase 3 (Cell Signaling) (Danvers, 
MA) via ELISA assays at 2- and 8-months for prevention and 2- and 6-months for 
delayed treatment rats. ELISA assays were carried out similar to in vitro experiments. 
 
 Protein activity levels were also determined by Western blot analysis with the 
following antibodies: total insulin receptor beta (1:500, Cellular Signaling) (Danvers, 
MA), phosphorylated insulin receptor beta (Tyr 1150/1151, 1:500, Cellular Signaling) 
(Danvers, MA), total Akt (1:500, Cellular Signaling) (Danvers, MA), phosphorylated Akt 
(Ser473, 1:500, Cellular Signaling) (Danvers, MA), total IRS-1 (1:500 Cellular Signaling) 
(Danvers, MA), and phosphorylated IRS-1 (Ser307, 1:500 Cellular Signaling) (Danvers, 
MA). 
 Statistical analysis was done to compare control, diabetic, and diabetic+49b using 
a Kruskal-Wallis analysis, with Dunn’s test post-hoc analyses.  P<0.05 was determined as 
significant. 
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Results 
 
Daily topical administration of 1mM Compound 49b did not affect body weight 
or blood glucose levels at 8-months time points (Table 4-1).  Body weight and blood 
glucose levels showed little variation between the 2- and 8-month time points.  There was 
also no observed effect on blood pressure or intraocular pressure following Compound 
49b treatment for 8-months.  In the delayed treatment studies, there were no observed 
effects on body weight, blood pressure, intraocular pressure, or blood glucose 
measurement in rats receiving treatment (Table 4-2).   
 
We have previously demonstrated that isoproterenol could decrease cleaved 
caspase 3 levels in REC and Müller cells cultured in hyperglycemic conditions at a dose 
of 10uM (Walker & Steinle 2007).  However isoproterenol induced cardiovascular 
changes (Grubb et al 1999); therefore, we developed a novel beta-adrenergic receptor 
agonist, Compound 49b to evaluate its ability to reduce markers of diabetic retinopathy in 
addition to reducing cardiovascular remodeling.  Our data indicated that there was no 
increase in diabetes-induced changes to the heart.   
 
 Caspase 3 is a pro-apoptotic protein whose cleavage and activation indicates cell 
death (Salvesen 2002).  Treatment with Compound 49b at the 50nM concentration 
significantly decreased caspase 3 levels in REC at the 30-minute time point and in Müller 
cells at the 24-hour time point (Figure 4-2).  These results show that Compound 49b is 
able to decrease a key marker of cell apoptosis in vitro. 
 
 Because inflammation is a characteristic of diabetic retinopathy (Joussen et al 
2009), protein levels of TNF-! were analyzed in REC and Müller cells cultured in high 
glucose.  Compound 49b treatment significantly reduced TNF-! levels after 1-hour at the 
50nM concentration in REC and at the 50nM concentration in Müller cells.  These results 
suggest that Compound 49b is able to significantly reduce inflammatory markers in vitro 
in hyperglycemic conditions. 
 
 To determine the optimal dose and time point for Compound 49b administration 
in vivo, rats were treated with streptozotocin (60mg/kg) to induce diabetes.  After 
2-months of diabetes, rats were treated for 4 days with varying doses of Compound 49b 
ranging from 1uM to 20mM to determine the optimal dose. Stimulation of 
beta-adrenergic receptors can increase cAMP accumulation, leading to PKA activation 
and CREB phosphorylation (Williams & Ford 2001).  PKA was therefore used as 
markers to show that Compound 49b actually reached the retina and elicited a response 
the appropriate cellular response.  We found that the 1mM Compound 49b showed the 
highest increase in PKA activity in comparison with the other administered doses (Figure 
4-3).  The 1mM concentration treatment was used for all subsequent experiments. 
 
  A-wave, b-wave amplitude, and oscillatory potential (OP) amplitude were 
measured monthly in each group via ERG analysis.  Data was obtained from animals at 
2-, 6-, and 8-months of diabetes for prevention group and at 6-, 8-, and 12-months in 
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delayed treatment group.  While there was little difference seen between ERG amplitudes 
of control rats and those receiving 1mM Compound 49b at 2-and 8-months, untreated    
Table 4-1. Prevention Study Vital Measurements. 
 
Groups   Body Weight 
 (g) 
Blood 
Glucose 
(mg/dL) 
Blood 
Pressure: 
Systolic 
Blood   
Pressure: 
Diastolic 
Intraocular 
Pressure 
Control   506.7±37.5  132.7±7.3 100.0±10.9 77.0±9.4  8.92±1.52 
Diabetic 
Diabetic 
+ 49b 
  273.1±40.5** 
248.7±8.3** 
 724.6±39.2* 
 695.8±62.2*** 
115.9±14.1 
104.8±13.6 
87.8±13.7
81.2±14.1 
  7.19±1.05* 
 8.08±1.17 
 
 
Table represents data on the control (Ctrl), Diabetic, and Diabetic+49b (Diab+49b) for 
body weight, glucose levels at 2-and 8-months of treatment, blood pressure and 
intraocular pressure. Data is mean±SD.  *P<0.05 vs. Ctrl.   ** p<0.01 vs. Ctrl.  *** p<0.001 
vs. Ctrl. 
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Table 4-2. Delayed Treatment Study Vital Measurements. 
 
Groups   Body Weight 
(g) 
Blood 
Glucose 
(mg/dL) 
Blood 
Pressure: 
Systolic 
Blood 
Pressure: 
Diastolic 
Intraocular 
Pressure 
Control 578.0±23.64   142.6±18.6  81.6±6.9 70.4±1.6 8.92±1.52 
Diabetic 
Diabetic 
+ 49b 
 283.3±3.52* 
 298.7±45.5*** 
748.7±3.3* 
  743.0±11.7* 
106.0±10.5 
103.2±10.6 
74.7±7.7 
79.0±8.8 
11.0±1.9 
10.8±2.2 
 
 
 
Table represents data on the control (Ctrl), Diabetic, and Diabetic+49b (Diab+49b) for 
body weight, glucose levels, blood pressure and intraocular pressure at 2-and 6-months of 
treatment with 6-months of pre-existing diabetes.  Data is mean±SD.  *P<0.05 vs. Ctrl.   ** 
p<0.01 vs. Ctrl.  *** p<0.001 vs. Ctrl. 
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Figure 4-2. Bar Graph of Cleaved Caspase 3 and TNF-! Protein Levels on 
Retinal Endothelial Cells. 
 
 
REC cultured in high glucose medium (top) and on Müller cells cultured in high glucose 
medium (bottom).  Cells were treated with Compound 49b for 30-and 60-minutes at the 
50nM, 100nM, and 10uM dosages.  *P<0.05 vs. NT, N=3 independent dishes for each 
time point. 
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Figure 4-3. PKA ELISA Results. 
Retinal lysates from diabetic rats treated with 1uM, 10um, 100uM, 1mM, 5mM, 10mM, 
and 20mM dosages for 4 days.  Rats receiving no treatment served as the controls. 
*P<0.05 vs. NT, N=4. 
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diabetic rats showed a significant reduction in b-wave amplitude, and oscillatory potential 
amplitudes (Figure 4-4).  This is significant to note because the b-wave is the major 
waveform that is reduced in diabetes and the OP is used to diagnose diabetic retinopathy.  
Excitingly, in the delayed treatment groups, b-wave amplitudes at 8-months of diabetes 
with 2-months of treatment were much improved compared to the diabetes alone group 
(which included the same rats before treatment), suggesting that Compound 49b 
treatment maintained electrical activity in the retina of rats in both studies (Figure 4-5). 
 
It has been previously demonstrated that diabetes decreases cell number and 
retinal thickness at 2-months (Barber et al 1998; Jiang et al 2010).  In both the peripheral 
and central retina, the thickness of the retina was significantly reduced in diabetic rats 
receiving no treatment (Figure 4-6).  The cell number in the ganglion cell layer (GCL) of 
the peripheral and central retinas were significantly reduced in diabetic rats as compared 
to control or diabetic+49b animals.  Data suggest that treatment with Compound 49b 
maintains the retinal thickness and cell number in spite of diabetes.  In addition, 
Compound 49b treatment was able to maintain retinal thickness and ganglion cell layer 
count similar to control rats in the delayed treatment studies. 
 
Compound 49b also significantly reduced the number of degenerate capillaries 
and pericyte ghost in comparison to diabetic only animals; however, values after 
Compound 49b treatment were still significantly different than control values.  The 
number of degenerate capillaries were also reduced to levels similar to control rats in the 
delayed treatment studies, while diabetic only rats showed significantly higher numbers 
(Figure 4-7). 
 
Because caspase 3 levels were reduced after receptor stimulation with Compound 
49b in vitro, levels were analyzed in vivo.  In both prevention and delayed treatment 
groups, untreated diabetic rats showed elevated levels of cleaved caspase 3 in comparison 
to control rats (Figure 4-8).  Rats treated for 2-months with 1mM Compound 49b showed 
levels of cleaved caspase 3 similar to those of the control rats.  Similarly, cleaved caspase 
3 levels of rats treated with 1mM Compound 49b were also similar to those of control 
rats in both groups after 8-months (prevention) and after 6-months (delayed), but were 
lower than untreated diabetic rats. 
 
 Because Akt activation is critical to the anti-apoptotic effects of insulin (Reiter et 
al 2006), protein levels of phosphorylated Akt were analyzed in retinal lysates of rats 
from each of the treatment groups.  Akt phosphorylation levels were significantly higher 
in rats treated with Compound 49b in comparison to non-treatment diabetic rats. Protein 
levels were significantly decreased in diabetic only rats when compared to control rats in 
both prevention and delayed treatment study groups (Figure 4-9).  It has been reported 
that stimulation of the insulin receptor beta occurs primarily at the tyrosine 1150/1151 
residues (Petruzelli et al 1984) in the rat; and that insulin receptors are present in the 
retina have high basal activity (Reiter et al 2006; Jiang et al 2010).  We found that 
treatment with Compound 49b maintained insulin receptor beta tyrosine phosphorylation.  
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Figure 4-4. ERG Waveforms and Graphs after Compound 49b Treatment  
from the Prevention Group.  
 
 
Panel A shows waveforms from one animal after 2-, 6-, and 8-months of treatment with 
Compound 49b.  Line graphs in each panel represent mean ± SD of the amplitude of rats 
of each of the three treatment groups.  The left column is a-wave amplitude, middle 
column is b-wave amplitude, and the far right column is the oscillatory potential 
amplitude. 
  
!
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Figure 4-5. ERG Waveforms and Graphs after Compound 49b Treatment from 
the Delayed Treatment Group.  
 
 
Top panel shows waveforms from animals after 6-months of diabetes and 2-and 6-months 
of treatment.  Line graphs in each panel represent mean ± SD of the amplitude of rats of 
each of the three treatment groups.  The left column is a-wave amplitude, middle column 
is b-wave amplitude, and the far right column is the oscillatory potential amplitude. 
 
 32
Figure 4-6. Results of Retinal Thickness and Ganglion Cell Layer Count. 
Top panel is a representative bar graph of retinal thickness and ganglion cell layer count 
in peripheral and central retinas in prevention group.  The bottom panel is a 
representative bar graph, which shows retinal thickness and ganglion cell layer count in 
peripheral and central retinas of animals from delayed treatment group.  *P<0.05 vs. Ctrl, 
N=5 independent subjects per group.  #P<0.05 vs. Diabetic (central retina), N=6 rats per 
group.  $P<0.05 vs. Diabetic (peripheral retina), N=6 rats per group. 
Below each graph are corresponding images of retinal thickness and ganglion layers. 
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Figure 4-7. Bar Graph of Acellular Capillaries per Millimeter Squared of Retinal 
Tissue and Pericyte Ghost Counts of Control (Ctrl), Diabetic, and Treatment Rats 
(Diab+49b).  
Top panel represents degenerate capillary counts in all treatment groups and pericyte 
ghost counts from prevention group, while bottom panel is representative of delayed 
treatment group.  Eye drop treatment reduced the number of degenerate capillaries and 
pericyte ghosts in treatment rats.  *P<0.05 vs. Ctrl, N=6 independent subjects per group.  
#P<0.05 vs. Diabetic, N=6 rats per group. 
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Figure 4-8. Results from Cleaved Caspase 3 ELISA on Retinal Lysates from 
Control (Ctrl), Diabetic, and Diabetic+Treatment Rats (Diab+49b).  
Rats were treated daily (Diab+49b) for 2-months and 6-, or 8-months.  Top panel shows 
cleaved caspase 3 levels after treatment in prevention study and bottom panel shows 
cleaved caspase 3 levels after Compound 49b topical treatment in the delayed treatment 
study.  *P<0.05 vs. Ctrl, N=6 rats in each group at each time point.  #P<0.05 vs. Diabetic, 
N=6 rats per group. 
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Figure 4-9. Bar Graph of the Ratio of Phosphorylated Akt and Total Akt Protein 
Levels.  
Top panel represents ratio of phosphorylated Akt to total Akt after treatment in 
prevention study.  Bottom panel represents the Akt ratio after treatment with Compound 
49b in delayed treatment study.  *P<0.05 vs. Ctrl, N=6 rats in each group at each time 
point.  #P<0.05 vs. Diabetic, N=6 rats per group. 
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Insulin receptor beta tyrosine phosphorylation was elevated to levels similar to 
control animals after 2-months of treatment compared to non-treatment diabetic rats 
(Figure 4-10).  Insulin receptor beta tyrosine phosphorylation was also maintained after 
8-months of diabetes in rats treated with Compound 49b.  Delayed treatment with 
Compound 49b showed that insulin receptor beta tyrosine phosphorylation levels were 
significantly elevated in comparison to non-treatment diabetic rats after both 2- and 
6-months of treatment.  These data suggest that Compound 49b can prevent the reduction 
of insulin receptor beta phosphorylation in diabetic rat throughout both treatment studies. 
 
Because a significant reduction in TNF-! levels was observed in vitro, levels were 
also assessed in vivo to insure that Compound 49b was able to decrease inflammatory 
marker levels in diabetic rats.  Prevention data show that after 2-months of treatment, 
protein levels of TNF-! were significantly elevated in non-treatment diabetic rats.  
Delayed treatment data showed that TNF-! protein levels were also significantly reduced 
post 2-months of treatment (Figure 4-11).  TNF-! levels were significantly elevated in 
non-treatment diabetic rats after 8-months of Compound 49b treatment and a similar 
elevation in TNF-! was seen after 12-months of diabetes in delayed treatment group. 
 
TNF-! has been shown to interfere with normal insulin signaling by inhibiting 
tyrosine phosphorylation of IRS-1, though phosphorylation of the serine307 residue of 
IRS-1 (IRS-1Ser307 ) (Sykiotis & Papavassiliou 2001).  A significant increase in TNF-! 
levels was observed in non-treatment diabetic rats throughout both studies in comparison 
to control rats (Figure 4-11).  After both 2-and 8-months of daily eye drop therapy, 
TNF-! levels were significantly reduced in comparison to non-treatment diabetic rats in 
the prevention study.  Similarly, IRS-1Ser307 was reduced in Compound 49b-treated 
retinal lysates in the delayed treatment groups, as compared to non-treatment diabetic rats 
(Figure 4-12).  Isoproterenol studies showed that diabetes-induced changes in heart 
structure were improved after treatment with 50mM topical application.  We reasoned 
that isoproterenol entered the systemic circulation to elicit this effect.  Compound 49b 
treatment produced no changes in heart structure changes compared to diabetic rats 
(Figure 4-13). 
 
 
Discussion 
 
 The goal of this study was to evaluate whether daily topical application of 1mM 
Compound 49b could effectively reduce vascular, neuronal, apoptotic, and inflammatory 
markers of diabetic retinopathy, while preventing cardiovascular remodeling.  In 
diabetes, modifications to the retina include basement membrane thickening, ganglion 
cell loss, capillary degeneration, inflammatory, and apoptotic marker level elevation 
(Wiley et al 2005).  The hyperglycemic environment produced by diabetes has also been 
reported to alter sympathetic nerves (Burnstock 1990), which may affect adrenergic 
receptor signaling.  We have previously demonstrated that loss of sympathetic 
innervation to the eye produces many of the same retinal features as diabetic retinopathy 
(Wiley et al 2005).  Application of eye drops was able to prevent and delay retinal  
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Figure 4-10. Bar Graph of the Ratio of Phosphorylated Insulin Receptor Beta 
(IRB) to Total Insulin Receptor Beta Protein Levels.  
Top panel represents the ratio of phosphorylated IRB to total IRB after Compound 49b 
daily treatment in prevention study rats.  Bottom panel represents the ratio of 
phosphorylated IRB to total IRB after Compound 49b daily treatment in delayed 
treatment study.  *P<0.05 vs. Ctrl, N=6 rats per group.  #P<0.05 vs. Diabetic, N=6 rats per 
group. 
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Figure 4-11. Results from TNF-! ELISA on Retinal Lysates from Control (Ctrl), 
Diabetic, and Diabetic+Treatment Rats (Diab+49b).  
Panel A shows TNF-! protein levels after treatment in prevention study while panel B 
shows levels after treatment with Compound 49b in delayed treatment study.  *P<0.05 vs. 
Ctrl, N=6 rat in each per group at each time point.  #P<0.05 vs. Diabetic, N=6 rats per 
group. 
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Figure 4-12. Bar Graph of the Ratio of Phosphorylated and Total Insulin Receptor 
Substrate-1 Protein Levels.  
Top panel represents the ratio of phosphorylated IRS-1 to total IRS-1 after Compound 
49b daily treatment in prevention study. Bottom panel represents the ratio of 
phosphorylated IRS-1 to total IRS-1 in rats that received delayed treatment with 
Compound 49b.  *P<0.05 vs. Ctrl, N=6 rats per group. #P<0.05 vs. Diabetic, N=6 rats per 
group. 
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Figure 4-13. Heart Images from Control, Diabetic, and Diabetic+Compound 49b 
Rats.  
Rats were treated daily with 1mM compound 49b and at 8-months heart images were 
obtained.  Top figure represents heart images at 8-months.  For bottom figures, left panel 
shows control (Ctrl) heart image, middle panel shows diabetic only, and right panel 
shows treated (Diab+49b) heart image.  No change in heart morphology was observed in 
treatment sample. *P<0.05 vs. Ctrl, N=1 rat per group. 
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damage; however, the isoproterenol treatment affected the heart (Jiang et al 2010). 
 
After screening various novel beta-adrenergic receptor agonists, we found that 
Compound 49b was able to reduce vascular and neuronal markers of diabetic retinopathy, 
without causing changes to the heart.  In this study, we do find any changes in the left 
ventricle following topical Compound 49b not treatment, which suggests that Compound 
49b does not repair diabetes-induced damage to the heart. 
 
In spite of affecting the heart, isoproterenol was effective at reducing 
inflammatory and apoptotic marker levels, vascular and neuronal markers, and improving 
insulin receptor signaling in the diabetic retina (Jiang et al 2010) but lost this effect over 
time.  Our data indicates that Compound 49b was able to reduce these markers and 
sustained this reduction throughout the duration of both studies.  While those diagnostic 
procedures used clinically to diagnose diabetic retinopathy, such as fluorescein 
angiography (Sinclair et al 1999), were not carried out, ERG analyses were used to 
evaluate retinal function.  Monthly ERG analyses showed a significant reduction in the 
loss of b waveform amplitudes after treatment with Compound 49b in both treatment 
groups, while a loss in function was observed in non-treatment rats.  Supporting the 
localized effect of Compound 49b, intraocular pressure, body weight, blood pressure, or 
glucose levels were not influenced by eye drop therapy.  A significant characteristic of 
diabetic retinopathy is formation of degenerate capillaries and pericyte ghosts (Kern & 
Engerman 1996) and these two were used as markers of vascular damage in these studies. 
Compound 49b was shown to reduce both markers in the delayed treatment and 
prevention study groups.  Compound 49b also improved neuronal measures in the retina, 
including preventing the loss of retinal thickness and cell number in the ganglion cell 
layer.  These two neuronal markers were reduced in both the central and peripheral 
retinas, indicating that Compound 49b was able to reduce vascular and neuronal changes 
associated with diabetes.  In addition to maintaining normal vascular and neuronal 
histology in the retina, Compound 49b eye drops also increased insulin receptor signaling 
and inhibited TNF-! levels and cleaved caspase 3.  
 
  Basal insulin levels in the retina are reduced in the diabetes (Reiter et al 2006). 
Our data support this finding that insulin receptor phosphorylation is significant reduced 
in retinal lysates from untreated diabetic rats.  Insulin has been reported to be a survival 
factor for R28 cells (a retinal ganglion cell line) (Xiaochua et al 2004), as well as retinal 
endothelial cells (Panjala & Steinle 2011).  The anti apoptotic actions of insulin occur 
through activation of Akt (Reiter et al 2006).  Upstream regulation of insulin receptor 
signaling in the retina is less well understood.  We have unpublished data to suggest that 
salmeterol, a selective beta-2-adrenergic receptor agonist, can significantly increase 
insulin receptor phosphorylation in retinal Müller cells, resulting in decreased apoptosis 
(data in submission).  The present data with Compound 49b shows that beta-adrenergic 
receptor signaling can increase both insulin receptor and Akt phosphorylation, followed 
by reduction in cleavage of caspase 3 levels therefore inhibiting apoptosis.  However, 
another aspect of Compound 49b’s actions may be involved.  Work in adipocytes and 
cardiac myocytes suggests that TNF-! can block the anti-apoptotic actions of insulin 
receptor through phosphorylation of serine307 on insulin receptor substrate-1.  In this 
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fashion, TNF-! is mediating a form of insulin resistance in these cell types.  Our data 
suggest that diabetes also induces increased IRS-1Ser307 phosphorylation in the retina, 
likely through the noted increased TNF-! levels in the diabetic retina.  Both of these 
actions are reduced following topical Compound 49b treatment.  Taken together, these 
data suggest that Compound 49b may prevent a form of retinal insulin resistance through 
decreased TNF-! levels, allowing the insulin receptor phosphorylation to be transduced 
to Akt and preventing apoptosis.   
 
 In conclusion, these results show that Compound 49b is able to prevent and delay 
the progression of retinal damage in diabetic rat retina.  In response to Compound 49b 
treatment, TNF-! and cleaved caspase 3 levels were decreased.  The reduction in TNF-! 
levels, likely prevented phosphorylation of IRS-1Ser307, allowing the insulin signal to be 
transduced to prevent apoptosis.  In this manner, Compound 49b may be preventing a 
form of insulin resistance in the retina, through maintenance of insulin receptor actions, 
despite hyperglycemia.  These results indicate that topical eye drop application of 
Compound 49b may possibly serve as a novel therapeutic for diabetic retinopathy. 
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CHAPTER 5.    SUMMARY AND CONCUSIONS 
 
 
Correlations: Clinical and Non-Clinical Findings of Diabetic Retinopathy 
 
Diabetic retinopathy can be characterized by lesions on the fundus, which 
characterize the disease.  These lesions include microaneurysms, hemorrhage spots, 
macular edema, and hard exudate formation (Viswanath & McGavin 2003).  While these 
lesions are non-specific to diabetes and the exact pathogenesis is unclear, these finding 
have been linked to pericyte degeneration or loss, a hallmark of diabetic retinopathy 
(Viswanath & McGavin 2003).  Compound 49b was shown to reduce pericyte loss in 
rats, linking our findings to published clinical findings of diabetic retinopathy.  It is 
necessary to note that microaneurysm count can be used as an indicator of progression of 
diabetic retinopathy, but microanuerysm count was not evaluated in the studies presented 
here.  Optical coherence tomography (OCT) images were however obtained from rats in 
all treatment groups (data not shown), showing that Compound 49b treatment appeared to 
reduce the loss of retinal thickness in rats.  OCT has been widely accepted as a 
quantitative measurement of retinal thickness (Sanchez-Tocino et al 2002), which is 
decreased in diabetic retinopathy. 
 
 
The Novel Compound 49b 
 
In this study, we investigated the effectiveness of a novel beta-adrenergic receptor 
agonist, Compound 49b, in the treatment of diabetic retinopathy.  Our in vitro and in vivo 
data suggests that topical treatment with Compound 49b in type 1 diabetic rats inhibits 
the hallmarks of diabetic retinopathy more effectively than a comparable non-selective 
beta-adrenergic receptor agonist, isoproterenol.  We demonstrate that Compound 49b was 
able to significantly reduce markers of inflammation and apoptosis in vitro and in vivo in 
streptozotocin-induced diabetic rats with limited systemic exposure. 
 
 
Effects of Diabetes on Beta-Adrenergic Receptor Signaling 
 
Beta-adrenergic receptors are located in the heart, the lungs, kidney, retina and 
almost every other organ.  In the heart, the presence of various beta-adrenergic receptor 
subtypes makes administration of beta-adrenergic receptor agonists critical.  For example, 
it has been shown that the use of a non-selective beta-adrenergic receptor agonist, 
isoproterenol increases heart rate and contractility (Whalen & Lewis 1999) when used for 
the treatment of the acute onset of asthma symptoms.  Work with isoproterenol for 
cardiovascular disease has shown that isoproterenol enters the systemic circulation to 
induce left ventricular hypertrophy (Nagano et al 1992).  Previous work in our lab with 
topical isoproterenol for diabetic retinopathy supported these findings, showing that the 
diabetes-induced damage to the heart was improved following isoproterenol therapy, 
indicating that isoproterenol likely entered the systemic circulation.  We did find that 
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isoproterenol was effective at restoring insulin signaling and neuronal and vascular 
changes associated with diabetic retinopathy in vitro at the 10uM and in vivo at the 
50mM concentrations; however, isoproterenol lost its effectiveness over time and 
produced systemic effects, which limited its usefulness clinically.  These findings led us 
to hypothesize that stimulation of beta-adrenergic receptors with a more selective 
beta-adrenergic receptor agonist may restore beta-adrenergic receptor signaling without 
producing systemic effects.  It was therefore necessary to formulate a novel 
beta-adrenergic receptor agonist and investigate its ability to prevent the onset of retinal 
manifestations of diabetic retinopathy. 
 
 
Advantages of Compound 49b over Isoproterenol 
 
Topical treatment with Compound 49b was shown to be more advantageous over 
topical treatment of isoproterenol in vivo.  Compound 49b is similar in structure to 
isoproterenol; with the addition of a N-substituent p-methoxyphenyl ring which helps the 
molecule lock into the beta-adrenergic receptor, leading to increased activity of 
Compound 49b as compared to isoproterenol.  We were able to measure the 
octanol-water partition coefficient (Log P) of isoproterenol and Compound 49b, which 
were 0.94 and 1.92, respectively.  While isoproterenol was found to be effective at 
reducing markers of diabetic retinopathy in culture and in vivo, topical Compound 49b 
treatment significantly reduced these same markers when administered at a lower 
concentration, 50nM and 1mM vs. 10uM and 50mM for isoproterenol.  Also, Compound 
49b did not appear to alter diabetes-induced damage to the heart, suggesting that topical 
Compound 49b did not reach the systemic circulation.  Finally, Compound 49b treatment 
was observed to prevent apoptosis and increase inflammatory mediators throughout the 
12-month duration of these studies without losing efficacy. 
 
 
Specific Findings of Compound 49b 
 
In addition to limited systemic exposure, Compound 49b was also able to reduce 
neuronal and vascular markers of diabetic retinopathy.  It has been reported that retinal 
thickness and the number of cells in the ganglion cell layer is reduced in STZ rats (Barber 
et al 1998).  While the exact pathophysiology of the disease is unknown, these results are 
beneficial and may add insight on the pathology of the disease.  In diabetic retinopathy, 
the blood supply to the layers of the retina is damaged and occluded, leading to hypoxia 
and cell damage and loss.  We see that with Compound 49b treatment that cell loss in the 
retina was reduced and retinal thickness were increased.  Clinical studies of diabetic 
retinopathy have primarily focused on identifying the source of vascular lesions to date. 
These combinations of vascular changes, unique to diabetic retinopathy, lead to 
decreased perfusion in the retina.  Vascular integrity is essential in to maintain to ensure 
proper delivery of nutrients and oxygen to retina.  In our present study two markers of 
vascular damage, pericyte loss and degenerate capillary formation were reduced after 
treatment with 1mM compound 49b.  These findings infer that treatment not only reduced 
loss of neuronal tissue, but also prevented the occurrence of vascular problems associated 
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with the disease. If we look into signaling molecules involved in the retina at the cellular 
level, we see other pathways that are influenced after Compound 49b treatment.  For 
example, as with isoproterenol studies insulin signaling, which is down regulated in 
diabetes, was increased significantly.  While insulin signaling and its involvement in 
diabetic retinopathy has received very little investigation, it has been shown that insulin 
signaling is reduced and that apoptosis of retinal cells are up-regulated in diabetes (Chen 
et al 2005).  Analyses of the key players in insulin signaling, in addition to apoptotic and 
inflammatory markers, were evaluated and showed an increase in insulin signaling, 
concurrent with a decrease in inflammation and apoptotic proteins.  Findings from the 
Compound 49b studies indicate that Compound 49b is more effective that isoproterenol, 
without side effects.  Future studies must be done to verify limited systemic toxicity. 
 
 
Potential Mechanisms of Action for Compound 49b 
 
Müller cells have been identified as a key player in the pathogenesis of diabetic 
retinopathy (Puro 2002).  Müller cells have been shown to secrete inflammatory 
cytokines, such as TNF-! and IL-1B, upon activation (Pannicke et al 2005).  It is worthy 
to note that inflammation is now recognized as a component of diabetic retinopathy 
(Joussen et al 2009) and may lead to the progression of microvascular and glial changes 
associated with the disease.  In diabetes, insulin signaling is down regulated (Reiter et al 
2006). It has also been shown that the insulin receptor is present in the retina (Chen et al 
2005) and that insulin receptor signaling possesses anti-apoptotic properties, resulting 
from activation of Akt (Geraldes et al 2009).  Work in our lab has demonstrated that 
TNF-! levels were significantly reduced after Compound 49b treatment compared to 
untreated diabetic retinal lysates.  
 
We also observed an increase in phosphorylation of Akt, likely leading to the 
observed decrease in the cleavage of caspase 3.  Literature suggests that TNF-! can 
influence insulin receptor signal signaling (Sykiotis & Papavassiliou 2001), leading to 
increased apoptosis.  TNF-! alters insulin receptor actions through phosphorylation of 
Ser307 phosphorylation on IRS-1, leading to inhibition of insulin receptor action (Luca & 
Olefsky 2008).  Tyrosine phosphorylation of IRS-1 can lead to an increase in Akt 
phosphorylation and a decrease in the cleavage of caspase 3, resulting in decreased cell 
death (Walker & Steinle 2007).  Because a reduction in TNF-! protein levels were 
observed along with a subsequent increase in Akt phosphorylation and decrease in 
caspase 3, we hypothesize that Compound 49b may decrease cell death in diabetic 
retinopathy through reduced IRS-1Ser307 phosphorylation, allowing for the restoration of 
insulin receptor signaling.  Future studies are ongoing to test this hypothesis.   
 
In retinal endothelial cells (REC), our data suggests that there is a separate 
mechanism by which Compound 49b may regulate apoptosis.  REC secrete insulin-like 
growth factor binding protein-3 (IGFBP-3).  The physiological action of IGFBP-3 is to 
regulate circulating insulin-like growth factor-1 (IGF-1) levels.  However, recently 
IGF-1-independent actions of IGFBP-3 have been reported (Yamada & Lee 2009). 
IGFBP-3 has been observed in the retina in the oxygen-induced retinopathy model, with 
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increased IGFBP-3 leading to a reduction in apoptosis of neovascular tufts (Lofqvist et al 
2007).  Data in our lab has shown that IGFBP-3 levels are reduced in high glucose and in 
the diabetic rat retina. With Compound 49b treatment, we observed an increase in 
IGFBP-3 levels in REC, along with a decrease in apoptotic markers Fas, FasL, Bax, and 
cytochrome-C.  To provide a potential mechanism, it is worthy to note that PKA levels 
were increased after Compound 49b treatment in REC cultured in high glucose.  
Subsequently, work carried out by other members in our lab has shown that after PKA 
inhibition using siRNA, Compound 49b-induced increases in IGFBP.-3 levels were 
reduced.  Similarly, Compound 49b was unable to inhibit REC apoptosis when combined 
with IGFBP-3 siRNA.  We hypothesize that beta-adrenergic receptor stimulation with 
Compound 49b reduces REC apoptosis by up-regulating PKA activity and increased 
IGFBP-3 levels.  Together this data suggests that Compound 49b regulates REC 
apoptosis via an IGF-1 independent, PKA-dependent pathway.  Ongoing studies are 
currently testing this hypothesis. 
 
 
Limitations to the Compound 49b Study 
 
In our studies, our results are very supportive of our overall hypothesis; however, 
there are always limitations.  While caspase 3 was used a marker of apoptosis, it is clear 
that a reduction in one protein does not directly correlate to reduced apoptosis. To further 
our studies on apoptosis, we can investigate other markers of apoptosis and use a Cell 
Death Detection ELISA to detect oligonucleosome formation.  It is also worth noting that 
delayed treatment data as done does not demonstrate that Compound 49b directly 
reverses diabetes induced changes.  Inclusion of data representing rats with no treatment 
at 8-and 12-months of diabetes without treatment may be able to begin to address 
whether Compound 49b can truly reverse diabetic-like changes in the retina.  The use of 
additional controls, such as rats receiving saline only injections and lower concentrations 
of Compound 49b, in our in vivo studies would allow the ability to make more exact and 
irrefutable conclusions about the effectiveness of Compound 49b.  The omissions of such 
controls are present, but do not disqualify literature-supported findings from the data 
presented. 
 
 
Future Studies 
 
In light of the data presented here, there are still other studies that must be carried 
out to offer more insight for translation of Compound 49b to patient care.  Further 
optimization and carrying out antagonist studies with specific beta-1, 2 adrenergic 
receptor agonists can show which receptor subtype the compound utilizes to modulate it 
effects.  In addition, pharmacokinetic studies will offer support for the antagonist study 
and offer insight on the systemic exposure of the drug via plasma sample analyses.  Radio 
ligand binding studies may potentially show that the drug actually binds the one or more 
of the beta-adrenergic receptor subtypes.  For our in vivo studies, inclusion of monitoring 
retinal changes in diabetic rats receiving no treatment for the duration of 12 months may 
be beneficial.  If promising data is obtained from the above experiments, efficacy and 
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toxicity studies may be appropriate to test the drug’s ability to efficiently work in vivo 
and to ensure that the drug does not cause adverse side effects. 
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